Followers | 11 |
Posts | 1455 |
Boards Moderated | 0 |
Alias Born | 02/01/2013 |
Wednesday, April 26, 2017 4:04:24 PM
Although it's for scaffolding, which Organovo doesn't need. At least now a ONVO lockstep with DDD will make more sense...
3D Systems and United Therapeutics Announce Bioprinting Agreement
BY PR Newswire
— 6:00 AM ET 04/26/2017
ROCK HILL, S.C. and SILVER SPRING, Md., April 26, 2017 /PRNewswire/ -- 3D Systems and United Therapeutics Corporation ( UTHR ) today announced plans to develop solid-organ scaffolds for human transplants. The multi-year collaboration and development agreement combines the 3D printing and precision healthcare expertise of 3D Systems ( DDD ) with the regenerative medicine and organ manufacturing capabilities of United Therapeutics ( UTHR ).
3D Systems ( DDD ) will collaborate with United Therapeutics ( UTHR ) and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC. The agreement focuses on development of 3D printing systems for solid-organ scaffolds, beginning with lung scaffolds.
The printing system will target collagen and other building block proteins as scaffold raw materials. Lung Biotechnology PBC will cellularize the scaffolds with patient-specific biological material, including re-differentiated stem cells.
"Our partnership with 3D Systems ( DDD ) is a major step forward in creating an unlimited supply of tolerable transplanted organs," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics ( UTHR ). "By cellularizing scaffolds created with 3D Systems ( DDD) printers with a patient's own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation."
"As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting," said Vyomesh Joshi, Chief Executive Officer of 3D Systems ( DDD ). "We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the caliber of United Therapeutics ( UTHR ) to provide healthcare solutions of the future."
"Combining the resources of United Therapeutics ( UTHR ) and 3D Systems ( DDD ) transforms our capability to tackle this difficult challenge," said Chuck Hull, Executive Vice President, Chief Technology Officer, 3D Systems ( DDD ). "This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems ( DDD ) as well as the domain knowledge of our technical partners at Lung Biotechnology PBC."
The collaboration and joint development will add another technology alternative to United Therapeutics' ( UTHR ) pursuit of an unlimited supply of organs for human transplantation.
"Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care problem," concluded Dr. Rothblatt. "Indeed, we expect one personalized organ transplant will avoid years of health care spending on palliative medical therapies."
Recent ONVO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/18/2024 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:05:26 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/26/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:05:07 PM
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis • GlobeNewswire Inc. • 07/16/2024 12:05:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/31/2024 08:05:33 PM
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease • GlobeNewswire Inc. • 05/21/2024 12:05:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/14/2024 04:45:20 PM
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) • GlobeNewswire Inc. • 05/14/2024 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:00:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/10/2024 09:15:22 PM
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering • GlobeNewswire Inc. • 05/09/2024 12:00:12 AM
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM